AxioMed and NanoFUSE Biologics to be Available for Acquisition

KICVentures seeks funding to prepare its spine portfolio companies, AxioMed and NanoFUSE Biologics, to be acquisition targets in the next three to five years. Assets include AxioMed Freedom™ cervical and lumbar disc replacements and NanoFUSE bioactive glass.

The AxioMed disc has an exclusive, 15-year license for its viscoelastic material and...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us